Inhibice signalizace B buněčným receptorem: první cílená léčba u chronické lymfocytární leukemie a dalších B buněčných lymfomů


This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on

Title in English Inhibition of B Cell Receptor Signaling: A First Targeted Th erapeutic Approach for Chronic Lymphocytic Leukemia and Other B Cell Lymphomas

MRÁZ Marek DOUBEK Michael MAYER Jiří

Year of publication 2013
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Central European Institute of Technology

Field Oncology and hematology
Keywords BCR signaling; B cell receptor; Btk protein; Syk protein; Lyn protein; PI3K; CAL-101; PCI-32765; R788
Attached files
Description Chronic lymphocytic leukemia (CLL) is the most frequent, yet by conventional therapy still incurable, leukemia in the Western world. Accumulating evidence of the role of B cell receptor (BCR) pathway in CLL B cell bio logy suggests the possible use of ’BCR inhibitors’ for targeted therapy. Recently published results of clinical trials of three diff erent molecules (fosfamatinib, ibrutinib and GS-1101) targeting BCR-associated kinases (Syk, Btk, PI3K) showed impressive clinical activity in CLL. These fi ndings will likely modify treatment approaches for chronic lymphocytic leukemia and some other B cell lymphomas in the near future. Herein, we review the data on BCR pathway deregulation in malignant CLL B cells, and the results of clinical trials utilizing fosfamatinib, ibrutinib and GS-1101.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info